Masonry Blog

CARTITUDE-4: Cilta-cel in Multiple Myeloma

The CARTITUDE-4 Trial: Groundbreaking Treatment for Multiple Myeloma The CARTITUDE-4 Trial, a pivotal study published in 2023, represents a significant advancement in the treatment of multiple myeloma, particularly for patients with lenalidomide-refractory disease. This Phase 3 randomized, open-label trial assessed … Read More

Featured Post

CAPItello-291: Capivasertib in Breast Cancer

The CAPItello-291 Trial: A New Horizon in Breast Cancer Treatment The CAPItello-291 Trial, a Phase III double-blind randomized trial conducted in 2023, has significantly contributed to the evolving landscape of breast cancer treatment, particularly for hormone receptor-positive advanced cases. Objective … Read More

Featured Post

BUCKLED Trial: US vs. XRay in Peds Forearm Fractures

The BUCKLED Trial: Ultrasound vs. Radiography in Pediatric Forearm Fractures In 2023, the BUCKLED Trial offered a novel perspective on diagnosing pediatric distal forearm fractures. This multicenter, open-label, noninferiority, randomized trial investigated whether ultrasonography could stand as a viable alternative … Read More

Featured Post

Baby-OSCAR: Ibuprofen in PDA

The Baby-OSCAR Trial: Evaluating Ibuprofen in Preterm Infants with PDA In 2024, the Baby-OSCAR Trial emerged as a pivotal study examining the effects of early treatment of patent ductus arteriosus (PDA) with ibuprofen in extremely preterm infants. This randomized, double-blind, … Read More

Featured Post

AGENT IDE: Paclitaxel-Coated Balloon for ISR

The AGENT IDE Trial: Revolutionizing the Treatment of In-Stent Restenosis The AGENT IDE Trial, a prominent study published in 2024, has shed light on a pivotal question in cardiology: Is a paclitaxel-coated balloon more effective than an uncoated balloon for … Read More

Featured Post

REDUCE LAP-HF II: Atrial Shunt Device in HFpEF and HFmEF

Insights from the REDUCE LAP-HF II Trial: Atrial Shunt Devices in Heart Failure Management The REDUCE LAP-HF II Trial, published in 2022, was a significant randomized, blinded, sham-controlled trial aiming to enhance the treatment for patients with heart failure. It … Read More

Featured Post

ILUMIEN IV: OCT-Guided vs. Angio-Guided PCI

Unveiling the ILUMIEN IV Trial: A New Era of Percutaneous Coronary Intervention The ILUMIEN IV: OPTIMAL PC Trial, conducted in 2023, is a landmark study that compares the efficacy of Optical Coherence Tomography (OCT)-guided coronary stent implantation to the traditional … Read More

Featured Post

BYPASS-CTCA: CT Angio before Cath in Patients with CABG

The BYPASS-CTCA Trial: Enhancing Cardiac Procedures with Pre-Operative CT Scans In 2023, the BYPASS-CTCA Trial set out to redefine the pre-operative protocol for patients with a history of coronary artery bypass grafting (CABG). This open-label randomized controlled trial posed a … Read More

Featured Post

DCD HEART Trial: Transplant in Circulatory Death

Pioneering Cardiac Care: Results from the DCD HEART Trial The DCD HEART Trial has broken new ground in the field of heart transplantation, examining the outcomes with donor hearts after circulatory death—a method that could potentially increase the donor pool … Read More

Featured Post

RUBY Trial Summary: Dostarlimab for Endometrial Cancer

The RUBY Trial: A New Chapter in Endometrial Cancer Treatment Recent results from the RUBY Trial have introduced a significant advancement in the treatment of primary advanced or recurrent endometrial cancer. The phase 3, randomized, double-blind trial meticulously evaluated the … Read More

Featured Post